Investigators involved in Phase-3 trials for HGCO19, India′s first mRNA vaccine, being developed by Gennova Biopharmaceuticals Limited, have stated that nearly 90% of trial volunteers have not experienced any side effect after receiving either one or two doses of the vaccine thus far. 

Dr Ashish Bavdekar, one of the principal investigators, who is leading the trials at Pune′s KEM Hospital Research Center, said that the data from the Phase-1 trial on vaccine immunogenicity was also encouraging, adding that the side effects, reported in a minority of participants, were very mild and not significant. He stated that some volunteers did not report any side effects. Dr Bavdekar added that the minor side effects included mild fever or headache. He added that the picture will be clear after the Phase 3 trials as the sample size was much larger for this phase… (ET Healthworld – TNN, December 18, 2021)